(FME) Fresenius Medical Care - Ratings and Ratios
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE0005785802
Dialysis Machines, Dialysis Solutions, Bloodlines, Water Systems, Pharma
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.82% |
| Yield on Cost 5y | 2.45% |
| Yield CAGR 5y | 1.82% |
| Payout Consistency | 97.7% |
| Payout Ratio | - |
| Risk via 5d forecast | |
|---|---|
| Volatility | 33.3% |
| Value at Risk 5%th | 47.0% |
| Relative Tail Risk | -14.04% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.78 |
| Alpha | -23.92 |
| CAGR/Max DD | 0.08 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.595 |
| Beta | 0.084 |
| Beta Downside | 0.022 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.77% |
| Mean DD | 15.58% |
| Median DD | 16.90% |
Description: FME Fresenius Medical Care January 02, 2026
Fresenius Medical Care AG & Co. KGaA (XETRA:FME) is the world’s largest provider of dialysis and related renal-care services, operating a network of outpatient clinics and hospital contracts in Germany, the United States, and other markets.
The business is split into two segments: **Care Delivery**, which runs the clinics and hospital-based dialysis services, and **Care Enablement**, which manufactures and distributes dialysis equipment (hemodialysis machines, peritoneal dialysis cyclers), consumables (dialyzers, concentrates, water-treatment systems), and renal pharmaceuticals.
Key recent metrics (FY 2023) show revenue of €19.4 bn, an EBITDA margin of ~23 %, and a 13 % year-over-year increase in US dialysis-clinic patient volume, reflecting both demographic aging and higher ESRD prevalence. The company’s growth is also tied to reimbursement trends in the U.S. Medicare-ESRD program and to its expanding home-dialysis offering, which benefits from policy incentives for cost-effective, patient-centric care.
For a deeper, data-driven assessment of FME’s valuation and risk profile, you may find the analyst tools on ValueRay useful for independent verification.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 718.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.94 > 1.0 |
| NWC/Revenue: 10.51% < 20% (prev 11.45%; Δ -0.93% < -1%) |
| CFO/TA 0.08 > 3% & CFO 2.51b > Net Income 718.2m |
| Net Debt (9.22b) to EBITDA (3.14b): 2.93 < 3 |
| Current Ratio: 1.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (292.1m) vs 12m ago -0.45% < -2% |
| Gross Margin: 25.00% > 18% (prev 0.25%; Δ 2475 % > 0.5%) |
| Asset Turnover: 61.97% > 50% (prev 59.18%; Δ 2.79% > 0%) |
| Interest Coverage Ratio: 3.98 > 6 (EBITDA TTM 3.14b / Interest Expense TTM 386.4m) |
Altman Z'' 2.66
| A: 0.07 (Total Current Assets 7.82b - Total Current Liabilities 5.76b) / Total Assets 30.89b |
| B: 0.38 (Retained Earnings 11.84b / Total Assets 30.89b) |
| C: 0.05 (EBIT TTM 1.54b / Avg Total Assets 31.70b) |
| D: 0.62 (Book Value of Equity 10.47b / Total Liabilities 16.98b) |
| Altman-Z'' Score: 2.66 = A |
Beneish M -3.08
| DSRI: 0.98 (Receivables 3.28b/3.28b, Revenue 19.64b/19.24b) |
| GMI: 1.01 (GM 25.00% / 25.14%) |
| AQI: 1.01 (AQ_t 0.54 / AQ_t-1 0.54) |
| SGI: 1.02 (Revenue 19.64b / 19.24b) |
| TATA: -0.06 (NI 718.2m - CFO 2.51b) / TA 30.89b) |
| Beneish M-Score: -3.08 (Cap -4..+1) = AA |
ValueRay F-Score (Strict, 0-100) 64.48
| 1. Piotroski: 6.50pt |
| 2. FCF Yield: 8.83% |
| 3. FCF Margin: 9.05% |
| 4. Debt/Equity: 0.81 |
| 5. Debt/Ebitda: 2.93 |
| 6. ROIC - WACC: 2.49% |
| 7. RoE: 5.21% |
| 8. Revenue Trend: 29.93% |
| 9. EPS Trend: data missing |
What is the price of FME shares?
As of January 28, 2026, the stock is trading at EUR 37.13 with a total of 815,792 shares traded.
Over the past week, the price has changed by +3.20%, over one month by -8.57%, over three months by -20.48% and over the past year by -18.41%.
Over the past week, the price has changed by +3.20%, over one month by -8.57%, over three months by -20.48% and over the past year by -18.41%.
Is FME a buy, sell or hold?
Fresenius Medical Care has no consensus analysts rating.
What are the forecasts/targets for the FME price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 45.6 | 22.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 37.6 | 1.3% |
FME Fundamental Data Overview January 27, 2026
Market Cap USD = 12.95b (10.92b EUR * 1.1859 EUR.USD)
P/E Trailing = 15.2541
P/E Forward = 8.7184
P/S = 0.556
P/B = 0.8331
P/EG = 0.3445
Revenue TTM = 19.64b EUR
EBIT TTM = 1.54b EUR
EBITDA TTM = 3.14b EUR
Long Term Debt = 6.32b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.14b EUR (from shortTermDebt, last quarter)
Debt = 10.47b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.22b EUR (from netDebt column, last quarter)
Enterprise Value = 20.14b EUR (10.92b + Debt 10.47b - CCE 1.26b)
Interest Coverage Ratio = 3.98 (Ebit TTM 1.54b / Interest Expense TTM 386.4m)
EV/FCF = 11.33x (Enterprise Value 20.14b / FCF TTM 1.78b)
FCF Yield = 8.83% (FCF TTM 1.78b / Enterprise Value 20.14b)
FCF Margin = 9.05% (FCF TTM 1.78b / Revenue TTM 19.64b)
Net Margin = 3.66% (Net Income TTM 718.2m / Revenue TTM 19.64b)
Gross Margin = 25.00% ((Revenue TTM 19.64b - Cost of Revenue TTM 14.73b) / Revenue TTM)
Gross Margin QoQ = 25.43% (prev 25.34%)
Tobins Q-Ratio = 0.65 (Enterprise Value 20.14b / Total Assets 30.89b)
Interest Expense / Debt = 0.89% (Interest Expense 93.1m / Debt 10.47b)
Taxrate = 18.69% (75.2m / 402.6m)
NOPAT = 1.25b (EBIT 1.54b * (1 - 18.69%))
Current Ratio = 1.36 (Total Current Assets 7.82b / Total Current Liabilities 5.76b)
Debt / Equity = 0.81 (Debt 10.47b / totalStockholderEquity, last quarter 12.95b)
Debt / EBITDA = 2.93 (Net Debt 9.22b / EBITDA 3.14b)
Debt / FCF = 5.18 (Net Debt 9.22b / FCF TTM 1.78b)
Total Stockholder Equity = 13.79b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.27% (Net Income 718.2m / Total Assets 30.89b)
RoE = 5.21% (Net Income TTM 718.2m / Total Stockholder Equity 13.79b)
RoCE = 7.64% (EBIT 1.54b / Capital Employed (Equity 13.79b + L.T.Debt 6.32b))
RoIC = 6.02% (NOPAT 1.25b / Invested Capital 20.76b)
WACC = 3.53% (E(10.92b)/V(21.39b) * Re(6.22%) + D(10.47b)/V(21.39b) * Rd(0.89%) * (1-Tc(0.19)))
Discount Rate = 6.22% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 1.78b)
Revenue Correlation: 29.93 | Revenue CAGR: 1.34% | SUE: N/A | # QB: 0
P/E Trailing = 15.2541
P/E Forward = 8.7184
P/S = 0.556
P/B = 0.8331
P/EG = 0.3445
Revenue TTM = 19.64b EUR
EBIT TTM = 1.54b EUR
EBITDA TTM = 3.14b EUR
Long Term Debt = 6.32b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.14b EUR (from shortTermDebt, last quarter)
Debt = 10.47b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.22b EUR (from netDebt column, last quarter)
Enterprise Value = 20.14b EUR (10.92b + Debt 10.47b - CCE 1.26b)
Interest Coverage Ratio = 3.98 (Ebit TTM 1.54b / Interest Expense TTM 386.4m)
EV/FCF = 11.33x (Enterprise Value 20.14b / FCF TTM 1.78b)
FCF Yield = 8.83% (FCF TTM 1.78b / Enterprise Value 20.14b)
FCF Margin = 9.05% (FCF TTM 1.78b / Revenue TTM 19.64b)
Net Margin = 3.66% (Net Income TTM 718.2m / Revenue TTM 19.64b)
Gross Margin = 25.00% ((Revenue TTM 19.64b - Cost of Revenue TTM 14.73b) / Revenue TTM)
Gross Margin QoQ = 25.43% (prev 25.34%)
Tobins Q-Ratio = 0.65 (Enterprise Value 20.14b / Total Assets 30.89b)
Interest Expense / Debt = 0.89% (Interest Expense 93.1m / Debt 10.47b)
Taxrate = 18.69% (75.2m / 402.6m)
NOPAT = 1.25b (EBIT 1.54b * (1 - 18.69%))
Current Ratio = 1.36 (Total Current Assets 7.82b / Total Current Liabilities 5.76b)
Debt / Equity = 0.81 (Debt 10.47b / totalStockholderEquity, last quarter 12.95b)
Debt / EBITDA = 2.93 (Net Debt 9.22b / EBITDA 3.14b)
Debt / FCF = 5.18 (Net Debt 9.22b / FCF TTM 1.78b)
Total Stockholder Equity = 13.79b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.27% (Net Income 718.2m / Total Assets 30.89b)
RoE = 5.21% (Net Income TTM 718.2m / Total Stockholder Equity 13.79b)
RoCE = 7.64% (EBIT 1.54b / Capital Employed (Equity 13.79b + L.T.Debt 6.32b))
RoIC = 6.02% (NOPAT 1.25b / Invested Capital 20.76b)
WACC = 3.53% (E(10.92b)/V(21.39b) * Re(6.22%) + D(10.47b)/V(21.39b) * Rd(0.89%) * (1-Tc(0.19)))
Discount Rate = 6.22% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 1.78b)
Revenue Correlation: 29.93 | Revenue CAGR: 1.34% | SUE: N/A | # QB: 0